Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07202884 · ClinicalTrials.gov registry record · Phase 3
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
A Phase 3 study of Urinary Incontinence,Stress, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT07202884 is a Phase 3 study of Urinary Incontinence,Stress that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,000 participants, above the 110-participant average among 3 other Urinary Incontinence,Stress trials with a reported enrollment target (809% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT07202884, a Phase 3 study of Urinary Incontinence,Stress, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during movement or activity such as coughing or exercising. Participation in the study will last about 58 weeks from screening to safety follow-up.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orforglipron
Study Locations (20)
Florida
- AMR Clinical - Fort Myers
- Altus Research - Lake Worth
- New Age Medical Research Corporation - Miami
- Emerald Coast OBGYN Clinical Research - Panama City
California
- Matrix Clinical Research - Los Angeles
- Alarcon Urology Center - Montebello
- Prestige Medical Group - Tustin
Alabama
- University of Alabama -The Kirklin Clinic - Birmingham
- AMR Clinical - Mobile
Pennsylvania
- OB/GYN Associates of Erie - Erie
- Clinical Research of Philadelphia - Philadelphia
Texas
- Next Level Urgent Care - Houston
- Innovative Medical Research of Texas - Houston
Virginia
- Health Research of Hampton Roads, Inc. - Newport News
- Urology of Virginia - Virginia Beach
Arizona
- Urologic Surgeons of Arizona - Mesa
Colorado
- Colorado Clinical Research - Lakewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2028-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07202884
The ClinicalTrials.gov registry entry for NCT07202884 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 110-participant average among 3 other Urinary Incontinence,Stress trials with a reported enrollment target (809% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Incontinence,Stress appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07202884 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT07202884 about?
NCT07202884 is a clinical study titled "A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight". The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during movement or activity ...
What is the current status of trial NCT07202884?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2025-09-30. Estimated completion is 2028-03.
What conditions does trial NCT07202884 study?
This clinical trial studies the following conditions: Urinary Incontinence,Stress.
What interventions are being tested in trial NCT07202884?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).
Who is sponsoring clinical trial NCT07202884?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07202884 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence,Stress
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.